Effects of human atrial natriuretic peptide on endogenous atrial natriuretic peptide and endothelin secretion in patients with pregnancy induced hypertension

AIM: To investigate the effects of human atrial natriuretic peptide (hANP) on endogenous atrial natriureticpeptide (ANP) and endothelin(ET) secretion in patients withpregnancy induced hypertension (PIH ). METHODS: 16 patients with PIH were infused intravenously with hANP (6μg/kg for 30 min). 12 patients with PIH were received placebosas controls. Plasma ANP and ET levels were measured by radioimmunoassay before and after infusion of hANP or placebo. Blood pressure changes and the clinical effects were observed. RESULTS: Infusion of hANP increased Plasma ANPsignificantly (P 0. of )and decreased ET but no significantdifference (P0. 05), plasma ANP/ET ratio was significantlyincreased (P0. 01 ). Mean artery pressure (MAP) was decreased (2. 3 ±1. 02 ) kPa. Proteinuria and edema were reduced markedly.' There was a positive correlation betweenchanges in plasma ANP and changes in MAP (P 0.01 ).There was no correlation between changes in plasma ET andchanges in MAP (P 0. 05 ). There were no significantchanges of plasma ANP,ET and ANP/ET ratio in the placebogroup. CONCLUSION: These results suggest that hANP induced endogenous ANP secretion and adjusted the imbalanceof ANP/ET ratio. The significant clinical effects of hANP inpatients with PIH may be related to its regulating effects onendogenous ANP and ET levels.